| http://www.w3.org/ns/prov#value | - BACKGROUND: Pharmacological antagonism of VLA-4 (Very Late Antigen 4, [alpha](4)[beta](1) integrin) has become an attractive target for the treatment of predominantly eosinophil mediated disease states such as asthma, allergic rhinitis, multiple sclerosis, rheumatoid arthritis, diabetes, and inflammatory bowel disease.
|
